EBV-gp350 confers B-cell tropism to tailored exosomes is a neo-antigen in normal and malignant B cells-a new option for the treatment of B-CLL

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Ruiss, Romana ^a   Jochum, Simon ^a   Mocikat, Ralph ^a   Hammerschmidt, Wolfgang ^a   Zeidler, Reinhard ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GLYCOPROTEIN; GLYCOPROTEIN 350; TUMOR ANTIGEN; UNCLASSIFIED DRUG; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; VIRUS ANTIGEN;

ARTICLE; B LYMPHOCYTE; BLAST CELL; CANCER IMMUNOTHERAPY; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EMBRYO; EPSTEIN BARR VIRUS; EXOSOME; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN TARGETING; T LYMPHOCYTE; TARGET CELL DESTRUCTION; TUMOR IMMUNOLOGY; VIRAL TROPISM; CD4+ T LYMPHOCYTE; CELL STRAIN HEK293; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; TROPISM; VIROLOGY; VIRUS ASSEMBLY;

HUMAN HERPESVIRUS 4;

ANTIGENS, VIRAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; EXOSOMES; HEK293 CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC; TROPISM; VIRAL MATRIX PROTEINS; VIRUS ASSEMBLY;

EID: 80053894454     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025294     Document Type: Article

References (36)

1. Avila-Carino J, Andersson J, Mellstedt H, Klein E, (1996) B-CLL cells experimentally infected with EBV enter DNA synthesis, produce cytokines and stimulate T-lymphocytes. Immunol Lett 54: 45-52.
2. Tomita Y, Avila-Carino J, Yamamoto K, Mellstedt H, Klein E, (1998) Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes. Immunol Lett 60: 73-79.
3. Nemerow GR, Wolfert R, McNaughton ME, Cooper NR, (1985) Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol 55: 347-351.
4. Hislop AD, Taylor GS, Sauce D, Rickinson AB, (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
5. Thery C, Ostrowski M, Segura E, (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9: 581-593.
6. Vallhov H, Gutzeit C, Johansson SM, Nagy N, Paul M, et al. (2011) Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J Immunol 186: 73-82.
7. Thery C, Zitvogel L, Amigorena S, (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-579.
8. Adhikary D, Behrends U, Feederle R, Delecluse HJ, Mautner J, (2008) Standardized and highly efficient expansion of Epstein-Barr virus (EBV)-specific CD4+ T cells using virus-like particles. J Virol 82: 3903-3911.
9. Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, et al. (2004) Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 104: 3257-3266.
10. Thery C, Duban L, Segura E, Veron P, Lantz O, et al. (2002) Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 3: 1156-1162.
11. Beauvillain C, Juste MO, Dion S, Pierre J, Dimier-Poisson I, (2009) Exosomes are an effective vaccine against congenital toxoplasmosis in mice. Vaccine 27: 1750-1757.
12. Kuate S, Cinatl J, Doerr HW, Uberla K, (2007) Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. Virology 362: 26-37.
13. Cantwell M, Hua T, Pappas J, Kipps TJ, (1997) Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3: 984-989.
14. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, et al. (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917-2924.
15. Takahashi S, Rousseau RF, Yotnda P, Mei Z, Dotti G, et al. (2001) Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 12: 659-670.
16. Wendtner CM, Kofler DM, Theiss HD, Kurzeder C, Buhmann R, et al. (2002) Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 100: 1655-1661.
17. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, et al. (2003) In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res 9: 2166-2172.
18. Avila-Carino J, Lewin N, Tomita Y, Szeles A, Sandlund A, et al. (1997) B-CLL cells with unusual properties. Int J Cancer 70: 1-8.
19. Mackus WJ, Frakking FN, Grummels A, Gamadia LE, De Bree GJ, et al. (2003) Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. Blood 102: 1057-1063.
20. Kater AP, Remmerswaal EB, Nolte MA, Eldering E, van Oers MH, et al. (2004) Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br J Haematol 126: 512-516.
21. Adhikary D, Behrends U, Boerschmann H, Pfunder A, Burdach S, et al. (2007) Immunodominance of lytic cycle antigens in epstein-barr virus-specific CD4+ T cell preparations for therapy. PLoS ONE 2: e583.
22. Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt W, et al. (2008) Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 3: e1464.
23. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, et al. (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84: 3158-3165.
24. Korz C, Pscherer A, Benner A, Mertens D, Schaffner C, et al. (2002) Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 99: 4554-4561.
25. Kronenberger K, Nossner E, Frankenberger B, Wahl U, Dreyling M, et al. (2008) A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia. J Immunother 31: 723-730.
26. Dilloo D, Brown M, Roskrow M, Zhong W, Holladay M, et al. (1997) CD40 ligand induces an antileukemia immune response in vivo. Blood 90: 1927-1933.
27. Kato K, Cantwell MJ, Sharma S, Kipps TJ, (1998) Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101: 1133-1141.
28. Biagi E, Yvon E, Dotti G, Amrolia PJ, Takahashi S, et al. (2003) Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther 14: 545-559.
29. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, et al. (2005) Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 11: 6916-6923.
30. Thery C, Amigorena S, Raposo G, Clayton A, (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3: Unit 3.22.
31. Steininger C, Rassenti LZ, Vanura K, Eigenberger K, Jager U, et al. (2009) Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest 39: 497-506.
32. Wallace LE, Wright J, Ulaeto DO, Morgan AJ, Rickinson AB, (1991) Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. J Virol 65: 3821-3828.
33. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, et al. (2004) CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 127: 404-415.
34. Graham FL, Smiley J, Russell WC, Nairn R, (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
35. Mautner J, Pich D, Nimmerjahn F, Milosevic S, Adhikary D, et al. (2004) Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol 34: 2500-2509.
36. Braut-Boucher F, Pichon J, Rat P, Adolphe M, Aubery M, et al. (1995) A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes. J Immunol Methods 178: 41-51.